** U.S.-listed shares of Biofrontera Inc fall 11% to 74 cents
** On Wednesday, company reported Q3 rev. of $9 mln, missing two analysts' average est. of $10 mln, due to disruption from hurricanes
** Q3 loss of 98 cents/shr wider than est. loss of 84 cents/shr, according to data compiled by LSEG
** BFRI likely to report strong Q4 revenue, as demand for Ameluz, company's treatment for a type of skin condition, increases in less-sunny weather - Brokerage Roth MKM
** Company to also benefit from Ameluz price hike of October and hurricane-interrupted sales moving into the quarter - Roth MKM
** Including session gains, BFRI down 73.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。